Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADAGIO-1 phase 3 study of KarXT + KarX-EC for agitation associated with Alzheimer's disease
CTR20260670Phase 3Active
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of xanomeline, trospium in Alzheimer's disease (AD), sponsored by Bristol Myers Squibb. Started Mar 2026; status: active.
02
Drugs
xanomelinetrospium
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on CTR20260670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260670.